Bob Bayer, Ph.D. joined Tanabe Research Labs in 2017. He has over 25 year’s experience in drug development at companies large and small, including Genentech, Novartis, Cytel, Neose Technologies, and Ajinomoto Althea. He has worked in the area of bioconjugation for 20 years, including 10 years of Antibody Drug Conjugate Process Development. He is an experienced CMC team leader and has extensive experience in leading cross functional development teams. Bob has an Honors BS Chem. from the University of Michigan, an MS and Ph.D. in Biochemistry from Cornell University, and did postdoctoral studies at Kyoto University and the University of California, San Diego.